Ali Rizvi to Treatment Outcome
This is a "connection" page, showing publications Ali Rizvi has written about Treatment Outcome.
Connection Strength
0.304
-
Current trends in diabetes management. JAAPA. 2005 Aug; 18(8):23-9.
Score: 0.111
-
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020 08; 109:154295.
Score: 0.078
-
"Thyrotoxic psychosis" associated with subacute thyroiditis. South Med J. 2007 Aug; 100(8):837-40.
Score: 0.032
-
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
Score: 0.021
-
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 03; 15(1):162.
Score: 0.015
-
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J. 2013 Dec; 166(6):1035-42.
Score: 0.012
-
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013 Sep; 6(9):914-22.
Score: 0.012
-
Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 2012 May 15; 8(1):87-93.
Score: 0.011
-
Normocalcemic primary hyperparathyroidism-characteristics and clinical significance of an emerging entity. Am J Med Sci. 2012 Feb; 343(2):163-166.
Score: 0.011